Here are some updates on drug research and technology from my reading-
Studies happening on drug based on a snake venom for potential heart failure treatment !
The Wall Street Journal reported, researchers believed that a drug, currently known as CD-NP, based on venom from the Eastern Green Mamba snake may be used to help very ill patients with heart failure. Early research on the drug indicated that it increased kidney function but did not greatly reduce blood pressure.
Study suggests acetaminophen makes vaccines less potent :
A study report sponsored by GlaxoSmithKline and published in The Lancet states "studies done in the Czech Republic, found that acetaminophen makes some vaccines less potent." CDC researchers said in an editorial that the "study offered 'a compelling case' against routine dosing but that the issue required more study.
European regulators grant orphan drug status to hepatocellular carcinoma treatment-
A leading Canadian medical journal published that, "Jennerex Inc.'s lead cancer drug called JX-594, could enjoy market exclusivity in Europe for a decade after a regulatory agency granted the company's product “orphan” drug status.
FDA rejects Rituxan for patients with earlier stages of Rheumatoid Arthritis-
The USFDA has rejected an application to expand the use of rheumatoid arthritis treatment Rituxan [rituximab] for patients with earlier stages of the disease, biotech drug developers Genentech Inc. and Biogen Idec said Saturday.
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
Studies happening on drug based on a snake venom for potential heart failure treatment !
The Wall Street Journal reported, researchers believed that a drug, currently known as CD-NP, based on venom from the Eastern Green Mamba snake may be used to help very ill patients with heart failure. Early research on the drug indicated that it increased kidney function but did not greatly reduce blood pressure.
Study suggests acetaminophen makes vaccines less potent :
A study report sponsored by GlaxoSmithKline and published in The Lancet states "studies done in the Czech Republic, found that acetaminophen makes some vaccines less potent." CDC researchers said in an editorial that the "study offered 'a compelling case' against routine dosing but that the issue required more study.
European regulators grant orphan drug status to hepatocellular carcinoma treatment-
A leading Canadian medical journal published that, "Jennerex Inc.'s lead cancer drug called JX-594, could enjoy market exclusivity in Europe for a decade after a regulatory agency granted the company's product “orphan” drug status.
FDA rejects Rituxan for patients with earlier stages of Rheumatoid Arthritis-
The USFDA has rejected an application to expand the use of rheumatoid arthritis treatment Rituxan [rituximab] for patients with earlier stages of the disease, biotech drug developers Genentech Inc. and Biogen Idec said Saturday.
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
